## Highlights of This Issue

### SPECIAL FEATURES

#### CCR Translations

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>511</td>
<td>Breast Cancer Stem Cells: We’ve Got Them Surrounded</td>
<td>Hasan Korkaya and Max S. Wicha</td>
</tr>
<tr>
<td>514</td>
<td>A Focus on PD-L1 in Human Melanoma</td>
<td>Peter Hersey and Stuart Gallagher</td>
</tr>
</tbody>
</table>

#### CCR New Strategies

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>517</td>
<td>New Strategies in Prostate Cancer: Translating Genomics into the Clinic</td>
<td>Himisha Beltran and Mark A. Rubin</td>
</tr>
</tbody>
</table>

#### CCR Drug Updates

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>524</td>
<td>Vandetanib for the Treatment of Medullary Thyroid Cancer</td>
<td>Nicole G. Chau and Robert L. Haddad</td>
</tr>
</tbody>
</table>

#### Molecular Pathways

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>530</td>
<td>Molecular Pathways: Targeted α-Particle Radiation Therapy</td>
<td>Kwamena E. Baidoo, Kwon Yong, and Martin W. Brechbiel</td>
</tr>
</tbody>
</table>

#### Perspective

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>538</td>
<td>Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer</td>
<td>Margaret A. Tempero, David Klimstra, Jordan Berlin, Tony Hollingsworth, Paula Kim, Nipun Merchant, Malcolm Moore, Doug Pleskow, Andrea Wang-Gillam, and Andrew M. Lowy</td>
</tr>
</tbody>
</table>

#### Review

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>541</td>
<td>Does Microenvironment Contribute to the Etiology of Estrogen Receptor–Negative Breast Cancer?</td>
<td>Mary Helen Barcellos-Hoff</td>
</tr>
</tbody>
</table>

## HUMAN CANCER BIOLOGY

### Deciphering the Mechanisms of Tumorigenesis in Human Pancreatic Ductal Epithelial Cells

Zhe Chang, Zhongkui Li, Xiaoyang Wang, Ya’an Kang, Yuhui Yuan, Jianguo Niu, Huamin Wang, Deyali Chatterjee, Jason B. Fleming, Min Li, James L. Abbruzzese, and Paul J. Chiao

### SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival

Mohamed Hassanein, Megan D. Hoeksema, Masakazu Shiota, Jun Qian, Bradford K. Harris, Heidi Chen, Jonathan E. Clark, William E. Albert, Rosana Eisenberg, and Pierre P. Massion

### Impact of Tumor Microenvironment and Epithelial Phenotypes on Metabolism in Breast Cancer

Heather Ann Brauer, Liza Makowski, Katherine A. Hoadley, Patricia Casbas-Hernandez, Lindsay J. Lang, Erick Román-Pérez, Monica D’Arce, Alex J. Freerman, Charles M. Perou, and Melissa A. Troester

## CANCER THERAPY: PRECLINICAL

### Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma

Silvia Xargay-Torrent, Mónica López-Guerra, Arnau Montraveta, Ifigenia Saborit-Villarroya, Laia Rosich, Alba Navarro, Patricia Pérez-Gaín, Gael Roué, Elias Campo, and Dolores Colomer

### The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

Xiaofeng Jiang, Jun Zhou, Anita Giobbie-Hurder, Jennifer Wargo, and F. Stephen Hodi

### Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function

Joan T. Garrett, Cammie R. Sutton, María Gabriela Kuba, Rebecca S. Cook, and Carlos L. Arteaga

---

The Journal of Clinical and Translational Research

February 1, 2013 • Volume 19 • Number 3

iii www.aacrjournals.org

Downloaded from clincancerres.aacrjournals.org on April 30, 2017. © 2013 American Association for Cancer Research.
A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal

Giuseppe Floris, Agnieszka Wozniak, Raf Sciot, Haifu Li, Lori Friedman, Thomas Van Looy, Jasmin Wellens, Peter Vermaelen, Christophe M. Derose, Jonathan A. Fletcher, Maria Debiec-Rychter, and Patrick Schöffski

Impairment of Glioma Stem Cell Survival and Growth by a Novel Inhibitor for Survivin–Ran Protein Complex

Hacer Guvenc, Marat S. Pavlyukov, Kaushal Joshi, Habibe Kurt, Yeshavanth K. Banasavadi-Siddegowda, Ping Mao, Christopher Hong, Ryoosuke Yamada, Chang-Hyuk Kwon, Deepak Bhasin, Somnundaram Chettiar, Gaspar Kitange, In-Hee Park, Jin N. Sarkaria, Chenglong Li, Mikhail L. Shakhparonov, and Ichiro Nakano

Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms


See commentary, p. 511

Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents


Systemic Administration of a Novel Immune-Stimulatory Pseudovirion Suppresses Lung Metastatic Melanoma by Regionally Enhancing IFN-γ Production

Kotaro Saga, Katsuto Tamai, Takehiko Yamazaki, and Yasufumi Kaneda

Antitumor Activity of Cell-Permeable RUNX3 Protein in Gastric Cancer Cells

Junghee Lim, Tam Duong, Nga Do, Phuong Do, Jaetaek Kim, Hyuncheol Kim, Wael El-Rifai, H. Earl Ruley, and Daewoong Jo

Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing

Fiamma Butilitta, Lara Felicioni, Maela Del Gramastro, Giampaolo Filice, Alessia Di Dorio, Sara Malatesta, Patrizia Viola, Irene Centi, Tommaso D’Antuono, Roberta Zappacosta, Sandra Rosini, Franco Cuccurullo, and Antonio Marchetti

Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression

Éric Lévesque, Shu-Pin Huang, Étienne Audet-Walsh, Louis Lacombe, Bo-Ying Bao, Yves Fradet, Isabelle Laverdière, Mélanie Rouleau, Chao-Yuan Huang, Chia-Cheng Yu, Patrick Caron, and Chantal Guilleminette

Detection of miR-34a Promoter Methylation in Combination with Elevated Expression of c-Met and β-Catenin Predicts Distant Metastasis of Colon Cancer

Helge Siemens, Jens Neumann, Rene Jackstadt, Ulrich Mansmann, David Horst, Thomas Kirchner, and Heiko Hermeking

γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)


Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma

Kimberley Jones, Frank Varri, Colm Keane, Pauline Crooks, Jamie P. Nourse, Louise A. Seymour, David Gottlieb, David Ritchie, Devinder Gill, and Maher K. Gandhi
ABOUT THE COVER

Cytology specimens may represent the only available material for molecular diagnosis in non–small cell lung cancer patients. When the number of neoplastic cells in these samples is very low in a large excess of nonneoplastic cells, the specimen is usually judged inadequate for mutation analysis with conventional methods. The cover figure shows a cytological smear obtained from a bronchoalveolar lavage with a limited number of tumor cells. Next-generation sequencing can greatly improve the detection of mutations in these cases. For details, see the article by Buttitta and colleagues on page 691 of this issue.